Navigation Links
Key to treating cancer may be finding its original cell
Date:8/11/2008

DURHAM, N.C. Cancer biologists are turning their attention to the normal cells that give rise to cancers, to learn more about how tumor growth might be stopped at the earliest opportunity.

"Identifying the specific, normal cells that cancers come from can provide critical insight into how cancers develop," said Robert Wechsler-Reya, an associate professor of Pharmacology and Cancer Biology at Duke University Medical Center. "This may help us develop more rational and effective approaches to treatment."

Every cancer comes from a normal cell. The hard part is finding the cell at the root of each particular subtype of cancer. For the first time, the Duke team has identified two types of cells in the brain that can give rise to the malignant brain tumor medulloblastoma. This dangerous cancer, which occurs most commonly in children, is currently treated with a combination of surgery, chemotherapy and radiation, which have extremely severe side effects, said Wechsler-Reya, who is a member of the Preston Robert Tisch Brain Tumor Center at Duke.

To find the normal cells at the root of medulloblastoma, Wechsler-Reya's laboratory, in collaboration with Brandon Wainwright's laboratory at the University of Queensland in Australia, created mouse models of medulloblastoma by turning off the patched gene, a key regulator of cell growth in the developing brain cerebellum. In particular, they tested the effects of shutting off patched in granule neuron precursors (GNPs), which can only make one particular type of nerve cell (neuron), or in stem cells, which can make all the different cell types in the cerebellum.

When they deleted patched in the neuron precursors, 100 percent of the mice developed medulloblastoma. Deleting patched from stem cells initially led to the formation of many more stem cells. However, most of these stem cells went on to form normal cell types within the cerebellum. Only the patched-less stem cells that gave rise to GNPs went on to form medulloblastoma tumors.

According to Wechsler-Reya, these studies provide the first definitive proof that medulloblastoma can be triggered in a granule neuron precursor or a stem cell. But even more importantly, they suggest that when it comes to cancer formation, the cell type in which a mutation happens is as important as the mutation itself. Although stem cells that lack patched also gave rise to other forms of brain cells, those cells did not form the tumors.

"Simply mutating a gene is not enough to cause cancer," Wechsler-Reya said. "The mutation has to happen in the right cell type at the right time. In the case of patched, GNPs provide the critical context for tumor formation."

Wechsler-Reya said that cancer biologists need to learn more about the genes that regulate proliferation (cell division), differentiation, survival, and programmed cell death in normal cells. A mutation in a proliferation gene, for example, can send the cell on a path of exaggerated division of cells -- becoming a fast-growing tumor. Understanding the way these genes are controlled during normal development can shed light on how they go awry in human cancers.


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Study provides clues to preventing and treating cancer spread
2. Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments
3. Treating rare breast cancer with radiation therapy may lower recurrence rate
4. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
5. Louisiana Improves Law for Treating Mentally Ill
6. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
7. New system devised to guide doctors treating patients with symptomatic myocardial bridging
8. NACDS Praises House Legislation to Delay Medicaid Cuts, Aid Pharmacies in Treating Patients
9. Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
10. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
11. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... latest in wound care advancements to physician colleagues, skilled nursing facility medical directors ... "Navigating the Treacherous Waters of Wound Care." , "At many of these conferences ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Pepper Flow promotional review platform at the Promotional Review Committee Compliance and ... help marketers streamline the medical, legal, and regulatory review (MLR) process – ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: